Eli Lilly and company LLY it is expected to release earnings results for the fourth quarter, before the opening bell on February 6, 2024.
Analysts expect the company to report quarterly profit of $2.19 per share, up from profit of $2.09 per share a year ago. The company is expected to post revenue of $8.93 billion, up from $7.3 billion in the year-earlier quarter, according to data from Benzinga Pro.
The company is reportedly engaged in negotiations with the German government to lift a ban on the public healthcare system covering the costs of weight loss treatments.
Eli Lilly shares rose 5.8% to close at $706.20 on Monday.
Benzinga readers can access the latest analyst ratings at Analyst stock ratings page. Readers can sort by stock title, company name, analyst firm, rating change or other variables.
Let’s look at how Benzinga is more accurate analysts rated the company in the recent period.
- Wells Fargo analyst Mohit Bansal maintained an Overweight rating and raised his price target from $650 to $700 on January 24, 2024. This analyst has an accuracy rate of 77%.
- Fiduciary Securities Analyst Robyn Karnauskas reiterated a Buy rating with a price target of $650 on November 29, 2023. This analyst has an accuracy rate of 63%.
- German bank Analyst James Shin initiated coverage on the stock with a Hold rating and a price target of $535 on November 9, 2023. This analyst has an accuracy rate of 73%.
- Morgan Stanley analyst David Phung maintained an Overweight rating and raised the price target from $673 to $722 on November 3, 2023. This analyst has an accuracy rate of 67%.
- Citigroup analyst Andrew Baum maintained a Buy rating and raised the price target from $525 to $675 on October 23, 2023. This analyst has an accuracy rate of 74%.
Read this next: Pinterest, Checkpoint Therapeutics and 2 other stocks are selling